MK 2140-010

A Randomized, Open-label, Multisite, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP versus R-CHOP in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) (waveLINE-010).

Ouvert à Saint-Cloud depuis le : 01/02/2025
Public cible : Adult
Phase : Phase III

Description de l'essai

To evaluate progression-free survival (PFS) in participants receiving zilovertamab vedotin plus R-CHP compared to those receiving R-CHOP.;To assess the complete response (CR) rate at the end of treatment.;To evaluate overall survival (OS).;To determine event-free survival (EFS).;To measure the duration of complete response.;To assess the safety and tolerability of the treatment regimen.

Url of the trial

Investigateur principal

CLEMENTINE SARKOZY

Médecin

Contacter